- Home
- CABA vs VACI Comparison
CABA vs VACI Comparison
Compare CABA & VACI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CABA | VACI |
|---|---|---|
| Founded | 2017 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.6M | 310.8M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | CABA | VACI |
|---|---|---|
| Price | $3.39 | $10.03 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $14.50 | N/A |
| AVG Volume (30 Days) | ★ 1.9M | 128.3K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.26 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.06 | $9.86 |
| 52 Week High | $3.78 | $10.07 |
Technical Indicators
Market Signals| Indicator | CABA | VACI |
|---|---|---|
| Relative Strength Index (RSI) | 63.99 | 63.89 |
| Support Level | $2.32 | $9.90 |
| Resistance Level | $3.73 | $10.04 |
| Average True Range (ATR) | 0.20 | 0.02 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 99.48 | 100.00 |
Price Performance
Historical ComparisonAbout CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
About VACI Viking Acquisition Corp. I Class A Ordinary Shares
Viking Acquisition Corp I is a blank check company.